Skip to main content
Equibles
MLYS logo

MLYS · Mineralys Therapeutics, Inc.

Track MLYS — free

Use MLYS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$28.21 -0.06 (-0.21%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$2.49B
Shares
88.41M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Net Income
-$154.65M +13%
FY2025 Net Income FY2022–FY2025
Diluted EPS
-$2.29 +37.4%
FY2025 Diluted EPS FY2022–FY2025
Operating Cash Flow
-$142.42M +14.4%
FY2025 Operating Cash Flow FY2022–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2025 FY2024 FY2023 FY2022
$301.59M $132.01M $168.58M $70.36M $26.25M
$69.2M $38.6M $23.82M $14.3M $5.23M
$39K $59K $43K $0 —
$370.79M $170.6M $192.4M $84.66M $31.48M
-$370.79M -$170.6M -$192.4M -$84.66M -$31.48M
$21.22M $15.95M $14.59M $12.76M $1.68M
— $0 — — —
-$349.58M -$154.65M -$177.81M -$71.9M -$29.8M
USD/shares -$4.16 -$2.29 -$3.66 -$1.99 -$5.77
USD/shares -$4.16 -$2.29 -$3.66 -$1.99 -$5.77
shares — 67.66M 48.54M 36.19M 5.17M
shares — 67.66M 48.54M 36.19M 5.17M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 8.17×
EV/EBIT
—
Peer median 17.01×
P/E (TTM)
—
Peer median 19.03×

Peer medians compare against the 245 similar-size Biotechnology companies (of 537 listed).

Key facts CIK 1933414 CUSIP 603170101 13F (30d) 170 filings 169 filers Visit website Investor relations